ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety ...
Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...
CAR T cells have made headlines for their ability to fight hematological cancers, but they have proven largely ineffective ...
Artiva Biotherapeutics is developing NK cell immunotherapy for autoimmune disease. Early trial data in B-cell lymphoma ...
Wang also acknowledges emerging platforms such as CAR NK cells and in vivo CAR T technologies but notes these remain ...
ImmunityBio stock jumps after strong trial updates in bladder cancer and lymphoma, with enrollment ahead of schedule and FDA ...
Techno-Science.net on MSN
A method to produce anti-cancer killer cells en masse
Natural killer cells, or NK cells, are elements of the immune system capable of rapidly locating and destroying cancerous or ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...
Teclistamab plus daratumumab delivers unprecedented progression-free survival benefits over standard of care in ...
News Medical on MSN
Lund researchers create "recipe book" for reprogramming immune cells to fight disease
In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the ...
GTB-5550 represents GT Biopharma's third NK cell engager advancing toward clinical development, targeting B7-H3, a protein prevalent across breast, lung, ovarian, pancreatic, prostate, bladder, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback